In the latest quarter, 9 analysts provided ratings for iRhythm Technologies IRTC, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 4 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 3 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Insights from analysts’ 12-month price targets are revealed, presenting an average target of $122.44, a high estimate of $145.00, and a low estimate of $100.00. A 10.19% drop is evident in the current average compared to the previous average price target of $136.33.
Decoding Analyst Ratings: A Detailed Look
A clear picture of iRhythm Technologies’s perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| William Plovanic | Canaccord Genuity | Raises | Buy | $137.00 | $122.00 |
| Joanne Wuensch | Citigroup | Lowers | Buy | $110.00 | $135.00 |
| Allen Gong | JP Morgan | Lowers | Overweight | $100.00 | $133.00 |
| Suraj Kalia | Oppenheimer | Lowers | Outperform | $145.00 | $165.00 |
| Mike Polark | Baird | Lowers | Outperform | $110.00 | $120.00 |
| Richard Newitter | Truist Securities | Lowers | Buy | $117.00 | $134.00 |
| David Saxon | Needham | Lowers | Buy | $119.00 | $138.00 |
| David Rescott | Truist Securities | Lowers | Buy | $134.00 | $145.00 |
| Cecilia Furlong | Morgan Stanley | Lowers | Overweight | $130.00 | $135.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they ‘Maintain’, ‘Raise’ or ‘Lower’ their stance, it reflects their reaction to recent developments related to iRhythm Technologies. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from ‘Outperform’ to ‘Underperform’. These ratings reflect expectations for the relative performance of iRhythm Technologies compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of iRhythm Technologies’s stock. This comparison reveals trends in analysts’ expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of iRhythm Technologies’s market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on iRhythm Technologies analyst ratings.
All You Need to Know About iRhythm Technologies
iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company’s portfolio includes ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for several days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.
iRhythm Technologies’s Economic Impact: An Analysis
Market Capitalization Analysis: Reflecting a smaller scale, the company’s market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: iRhythm Technologies’s revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 19.27%. This indicates a substantial increase in the company’s top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: iRhythm Technologies’s net margin surpasses industry standards, highlighting the company’s exceptional financial performance. With an impressive -13.58% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): iRhythm Technologies’s ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -21.22%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): iRhythm Technologies’s ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.2%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 7.43, caution is advised due to increased financial risk.
The Core of Analyst Ratings: What Every Investor Should Know
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street’s Next Big Mover
Benzinga’s #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
This post was originally published on here
